



12-18-01

Express Mail No.: EL 477 032 796 US

TECH CENTER 1600/2900

Box 2121  
Dec 21 2001

OPIPE  
RECEIVED  
#13/c  
1-2-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Karsenty et al.

Application No.: 09/489,873

DEC 14 2001

Group Art Unit: 1635

Filed: January 20, 2000

Examiner: Lacourciere, K.

For: METHODS AND COMPOSITIONS  
FOR CONTROL OF BONE  
FORMATION VIA MODULATION OF  
LEPTIN ACTIVITY

Attorney Docket No.: 9142-006-999

Assistant Commissioner for Patents

Box Sequence Listing

Washington, DC 20231

Sir:

In response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed November 20, 2001 in connection with above-identified application, Applicants submit concurrently herewith: (a) a Sequence Listing in paper and computer readable form pursuant to 37 C.F.R. §1.821(c) and (e); and (b) a return copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.

I hereby state that the content of the paper and computer readable copies of the substitute Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c), (d) and (e), respectively, are the same. I hereby state that the submission herein under 37 C.F.R. §1.821(g) does not include new matter.

Please enter the enclosed substitute paper copy into the specification as a replacement of the paper copy submitted on October 5, 2001.

RECEIVED

DEC 21 2001

TECH CENTER 1600/2900

It is estimated that no fee is required for filing this Response. In the event a fee is due, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 1150.

Date December 14, 2001

Respectfully submitted,

By: Stephen L. S. Abrams Reg. No. 43,149

Samuel B. Abrams 30,605  
Samuel B. Abrams (Reg. No.)

PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

**O I P E**  1: This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).

**O I P E**  2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

**O I P E**  3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

**O I P E**  4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

7. Other: Sequences not identified by SEQ ID NO:#

**Applicant Must Provide:**

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**